Xencor stock skyrockets 26% overnight after breakthrough in cancer research
Xencor, Inc., a clinical-stage biopharmaceutical company specializing in engineered antibodies for cancer treatment, saw its stock rise by 26% to $20.39 on Monday following substantial ... Read More
AstraZeneca to acquire Fusion Pharmaceuticals to boost cancer radioconjugate development
In a strategic move to revolutionize cancer treatment, AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a pioneer in the development of ... Read More
Protagonist Therapeutics secures $22m to advance IBD treatment
Protagonist Therapeutics, a clinical-stage biopharmaceutical company specializing in the discovery and development of novel peptide-based drugs, has successfully raised $22 million in new equity financing. ... Read More